Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

NCT01067443 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

OTHER

Sponsor class

Conditions

Primary Visceral Leishmaniasis

Interventions

DRUG: Liposomal amphotericin B (AmBisome®) and sodium stibogluconate
DRUG: Liposomal amphotericin B + miltefosine
DRUG: Miltefosine

Sponsor

Drugs for Neglected Diseases

Collaborators

[object Object]
[object Object]